MedPath

Sumatriptan

Generic Name
Sumatriptan
Brand Names
Imitrex, Onzetra, Sumavel, Tosymra, Treximet, Zembrace
Drug Type
Small Molecule
Chemical Formula
C14H21N3O2S
CAS Number
103628-46-2
Unique Ingredient Identifier
8R78F6L9VO

Overview

Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines. Sumatriptan was granted FDA approval on 28 December 1992.

Indication

A combination sumatriptan and naproxen tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older. Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults. One of the subcutaneous formulations of sumatriptan is also indicated to treat cluster headaches in adults, while the other subcutaneous formulation is not.

Associated Conditions

  • Acute Migraine
  • Acute Cluster headaches

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/07/23
Not Applicable
Completed
2024/07/16
N/A
Recruiting
2022/12/16
Not Applicable
Completed
2022/01/27
Not Applicable
Completed
2021/11/05
Phase 4
Completed
2021/10/01
Phase 1
Completed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
2021/07/01
Phase 3
UNKNOWN
2020/12/30
Early Phase 1
UNKNOWN
2020/04/21
Phase 1
Completed
2020/02/06
Phase 4
Completed
Damanhour Teaching Hospital

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
MedVantx, Inc.
66116-413
ORAL
50 mg in 1 1
9/3/2009
Mylan Pharmaceuticals Inc.
0378-5631
ORAL
50 mg in 1 1
7/16/2018
Physicians Total Care, Inc.
54868-5978
ORAL
100 mg in 1 1
5/24/2010
Innovida Phamaceutique Corporation
71800-901
ORAL
85 mg in 1 1
12/9/2020
GlaxoSmithKline LLC
0173-0523
NASAL
20 mg in 1 1
3/22/2024
Cipla USA Inc.
69097-644
NASAL
20 mg in 1 1
1/29/2021
Direct_Rx
72189-404
ORAL
100 mg in 1 1
3/6/2023
DIRECT RX
61919-408
ORAL
50 mg in 1 1
6/7/2016
Baxter Healthcare Corporation
36000-289
SUBCUTANEOUS
6 mg in 0.5 mL
10/6/2021
Advanced Rx Pharmacy of Tennessee, LLC
80425-0224
ORAL
100 mg in 1 1
1/12/2023

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
IMIGRAN INJECTION 6 mg/0.5 ml
SIN06744P
INJECTION
6 mg/0.5 ml
12/26/1991
SUMATRAN TABLET 50MG
SIN13667P
TABLET
50mg
6/26/2009
IMIGRAN TABLET 50 mg
SIN08419P
TABLET, FILM COATED
50 mg( Equivalent to 70mg as Succinate)
10/26/1995
SUMASON TABLETS 50MG
SIN17179P
TABLET, FILM COATED
50mg
2/12/2025

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Sumatriptan Succinate Capsules
国药准字H20040699
化学药品
胶囊剂
8/3/2020
Sumatriptan Succinate Tablets
国药准字H20030086
化学药品
片剂
5/28/2020
Sumatriptan Succinate Tablets
国药准字H20040700
化学药品
片剂
8/21/2020

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.